Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: A prospective study of feasibility, safety, and healthcare resource use

Background: We evaluated feasibility, safety, and total resource use of subcutaneous immunoglobulin (SCIG) in a pilot study of patients who underwent allogeneic hematopoietic cell transplant (HCT) over a 6-month period. Methods: A total of 20 eligible patients were treated with SCIG at 0.1 g/kg/week...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Ivan Pasic, Wael Alanazi, George Dranitsaris, Lani Lieberman, Auro Viswabandya, Dennis Dong Hwan Kim, Jeffrey H. Lipton, Fotios V. Michelis
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Wolters Kluwer Medknow Publications 2021-10-01
سلاسل:	Hematology/Oncology and Stem Cell Therapy
الموضوعات:	allogeneic hematopoietic cell transplant feasibility hypogammaglobulinemia pilot study subcutaneous immunoglobulin
الوصول للمادة أونلاين:	https://journals.lww.com/10.1016/j.hemonc.2021.01.001
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!